Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody

Am J Hematol. 2016 Dec;91(12):E506-E508. doi: 10.1002/ajh.24563. Epub 2016 Oct 21.

Authors

Morie A Gertz¹, Heather J Landau², Brendan M Weiss³

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota.
² Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Abramson Cancer Center, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / immunology*
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Immunoglobulin Light-chain Amyloidosis / pathology
Male
Middle Aged

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
birtamimab